Clinical TrialJul 1, 2026, 08:01 AM
NewAmsterdam Pharma to Present Obicetrapib Alzheimer's Prevention Data
AI Summary
NewAmsterdam Pharma announced it will present data on obicetrapib's potential for early Alzheimer's disease prevention at the Alzheimer's Association International Conference (AAIC) 2026. Analysis from the BROADWAY trial showed statistically significant lower absolute changes in p-tau217, a key Alzheimer's biomarker, compared to placebo over 12 months in both the full analysis set and in ApoE4 carriers. The drug was also well-tolerated in the trial, with safety results comparable to placebo, highlighting its multi-pathway effects beyond LDL-C lowering.
Key Highlights
- NewAmsterdam Pharma to present obicetrapib data for Alzheimer's prevention at AAIC 2026, July 12-15.
- Data from BROADWAY trial shows obicetrapib's potential as a novel, oral therapy for early Alzheimer's prevention.
- Statistically significant lower absolute changes in p-tau217 (p=0.025; n=1,535) observed in full analysis set.
- Statistically significant lower p-tau217 changes (p=0.022; n=367) also seen in ApoE4 carriers.
- Favorable trends noted in other Alzheimer's biomarkers including NFL, GFAP, p-tau181, and Aβ42/40 ratio.
- Obicetrapib was well-tolerated in the BROADWAY trial, with safety comparable to placebo.
- Company completed enrollment of the Phase 3 PREVAIL cardiovascular outcomes trial in April 2024 with over 9,500 patients.
Price Impact
More from NAMS